Cocrystal Pharma, Inc. Files Form 8-K – Key Updates for Investors

Cocrystal Pharma, Inc. has filed a Form 8-K with the U.S. Securities and Exchange Commission, dated March 10, 2026. This filing is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 and offers important updates regarding the company. Below is a detailed breakdown of the key points and their implications for shareholders and potential investors.

Key Points from the Report

• Filing Type: Form 8-K – Current Report
• Date of Report: March 10, 2026
• Registrant Name: Cocrystal Pharma, Inc.
• SEC File Number: 001-38418
• Business Address: 19805 N. Creek Parkway, Bothell, WA 98011
• Trading Symbol: COCP
• Exchange: NASDAQ Capital Market

Important Information for Shareholders

• Departure/Election/Appointment of Directors and Officers:
  • The filing references Item 5.02: “Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers”. However, the actual details about any departures, elections, appointments, or changes in compensatory arrangements are not provided in the visible portion of the filing. The section is listed, but no substantive content is shown. If any such events had occurred, they could be material and potentially price-sensitive, affecting the company’s governance and outlook. Based on the document, no actionable news is disclosed.
• Emerging Growth Company Status:
  • Cocrystal Pharma, Inc. does NOT qualify as an emerging growth company under Rule 405 of the Securities Act of 1933, which means it is not eligible for certain reduced reporting requirements and exemptions. This status may impact compliance costs and transparency but is not immediately price-sensitive.
• Pre-commencement Communications:
  • The company indicates false for pre-commencement tender offer communications and issuer tender offers. There are no written communications under Rule 425 and no soliciting materials under Rule 14a-12. This means there are no pending merger, acquisition, or tender offer activities disclosed in this filing.
• Securities Registered:
  • The only security registered pursuant to Section 12(b) is the Common Stock, traded on NASDAQ under the ticker COCP.

Material or Price-Sensitive Information

Based on the contents of this Form 8-K filing, there are no material events, transactions, or disclosures that are likely to affect the share price or represent price-sensitive information for investors. The filing appears to be a standard administrative or compliance update, with no actionable news regarding management changes, financial results, M&A activity, or other corporate actions.

Conclusion

Investors should note that while the Form 8-K references Item 5.02, there are no details provided about any director or officer changes, nor any corporate events that would impact the company’s strategic direction or share value. The filing confirms the company’s status and compliance with relevant SEC rules but does not disclose any information that would be considered price-moving or newsworthy.

Action: No investor action is recommended based on this filing. Continue monitoring Cocrystal Pharma, Inc. for future updates or material events.

Disclaimer

The information provided above is based on a review of the SEC Form 8-K filing of Cocrystal Pharma, Inc. dated March 10, 2026. No material events are disclosed in this filing. This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with financial advisors before making any investment decisions.

View Cocrystal Pharma, Inc. Historical chart here